Investigational Drug Information for CC-92480
✉ Email this page to a colleague
What is the drug development status for CC-92480?
CC-92480 is an investigational drug.
There have been 15 clinical trials for CC-92480.
The most recent clinical trial was a Phase 1 trial, which was initiated on September 30th 2022.
The most common disease conditions in clinical trials are Neoplasms, Plasma Cell, Multiple Myeloma, and Liver Diseases. The leading clinical trial sponsors are Celgene, Bristol-Myers Squibb, and Abdullah Khan.
There are two US patents protecting this investigational drug and eighteen international patents.
Summary for CC-92480
| US Patents | 2 |
| International Patents | 18 |
| US Patent Applications | 19 |
| WIPO Patent Applications | 10 |
| Japanese Patent Applications | 4 |
| Clinical Trial Progress | Phase 1 (2022-09-30) |
| Vendors | 28 |
Recent Clinical Trials for CC-92480
| Title | Sponsor | Phase |
|---|---|---|
| A Study to Evaluate Alnuctamab in Combination With Mezigdomide in Participants With Relapsed and/or Refractory Multiple Myeloma | Celgene | Phase 1/Phase 2 |
| A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of BMS-986393 in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma | Juno Therapeutics, Inc., a Bristol-Myers Squibb Company | Phase 1 |
| Elotuzumab, CC-92480, and Dexamethasone for the Treatment of Relapsed or Refractory Myeloma After CD38- and BCMA-Targeted Therapies | Abdullah Khan | Phase 1 |
Clinical Trial Summary for CC-92480
Top disease conditions for CC-92480
Top clinical trial sponsors for CC-92480
US Patents for CC-92480
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| CC-92480 | ⤷ Sign Up | Antiproliferative compounds and methods of use thereof | Celgene Corporation (Summit, NJ) | ⤷ Sign Up |
| CC-92480 | ⤷ Sign Up | Antiproliferative compounds and methods of use thereof | Celgene Corporation (Summit, NJ) | ⤷ Sign Up |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for CC-92480
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| CC-92480 | Argentina | AR112268 | 2037-07-10 | ⤷ Sign Up |
| CC-92480 | Australia | AU2018301335 | 2037-07-10 | ⤷ Sign Up |
| CC-92480 | Australia | AU2022287569 | 2037-07-10 | ⤷ Sign Up |
| CC-92480 | Brazil | BR112020000442 | 2037-07-10 | ⤷ Sign Up |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
